Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly and Company is leading a global effort to protect wildlife by shifting away from horseshoe crab blood and using a ...

European pharmaceutical bosses have called on the EU to increase drug prices towards the much higher levels paid by the US, ...

The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

As previously reported, Cantor Fitzgerald initiated coverage of Eli Lilly (LLY) with an Overweight rating and $975 price target Lilly is off ...